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A Humanized Hypertrophic 
Cardiomyopathy Model to Elucidate 
the Molecular Mechanism in Disease 
Pathology 
Hypertrophic Cardiomyopathy (HCM) 
•  Most prevalent genetic heart condition  
 
•  Enlarged cardiomyocytes = Enlarged heart  
 
•  Thickened left ventricular wall 
 
•  Arrhythmia induced Sudden Cardiac Death (SCD) 
Hypertrophic Cardiomyopathy (HCM) 
• Heterogenous genetic mutations  
 
• Human Cardiac biopsies – Difficult, Invasive & Short-
Shelf life 
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Our Approach 
• Induced Pluripotent Stem Cells (iPSCs)  
•  Ethical  
•  Non-Invasive 
•  Immortal cell line 
 
• Multiple Cell lines 
•  Heterogeneity of disease causing mutations  
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Cardiac Differentiation 
HCM-CMs Display Clinical Phenotypes  
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Proposed Mechanism  
•  Abnormal ratio of Ryanodine 
Receptors to SERCA 
•  Ryanodine Antagonists – Dantrolene 
•  Gene Knockdown/Knock-in 
•  Creation of a Multiscale Cardiac 
Model 
 
	
Significance  
•  Generation of humanized HCM models 
 
•  Ethical, non-invasive, efficient (high throughput, long shelf-life) 
 
•  Potential for Personalized Medicine  
 
•  Findings provide foundation and direction for future research 
Types of Hypertrophic Cardiomyopathy 
Cardiac Differentiation 
•  iPSCs dispersed into small clumps via dispase 
•  Cells were aggregated in aggrewells (5000 cells/well), centrifuged 
and incubated overnight 
•  Cells were seeded on low attachment dishes on day 2 
•  Medium changed on day 4 and day 6 
•  Embryoid bodies plated on gelatin-coated dishes on day 8 
•  Beating areas observed between day 11-14 
•  Specific growth factors used: BMP4, FGF2 (Day 1-4), VEGF, IWP4 
(day 4-8) 
